Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine

This study has been terminated.
(Slow enrollment)
Eli Lilly and Company
Information provided by (Responsible Party):
Joseph Calabrese, MD, University Hospitals Cleveland Medical Center Identifier:
First received: September 13, 2005
Last updated: October 3, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2006
  Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)